Table of Pharmacogenomic Biomarkers in Drug Labeling
Contact Us
- FDA CDER Genomics pharmacogenomics@fda.hhs.gov
- Division of Translational and Precision Medicine (DTPM)
Pharmacogenomics can play an important role in identifying responders and non-responders to medications, avoiding adverse events, and optimizing drug dose. Drug labeling may contain information on genomic biomarkers and can describe:
- Drug exposure and clinical response variability
- Risk for adverse events
- Genotype-specific dosing
- Mechanisms of drug action
- Polymorphic drug target and disposition genes
- Trial design features
The table below lists therapeutic products from Drugs@FDA with pharmacogenomic information found in the drug labeling. The labeling for some, but not all, of the products includes specific actions to be taken based on the biomarker information. Pharmacogenomic information can appear in different sections of the labeling depending on the actions. For more information, please refer to the appropriate labeling guidance.
Biomarkers in the table include but are not limited to germline or somatic gene variants (polymorphisms, mutations), functional deficiencies with a genetic etiology, gene expression differences, and chromosomal abnormalities; selected protein biomarkers that are used to select treatments for patients are also included.
This table does not include non-human genetic biomarkers (e.g., microbial variants that influence sensitivity to antibiotics), biomarkers that are used solely for diagnostic purposes (e.g., for genetic diseases) unless they are linked to drug activity or used to identify a specific subset in whom prescribing information differs, or biomarkers that are related to a drug other than the referenced drug (e.g., influences the effect of the referenced drug as a perpetrator of an interaction with another drug). For drugs that are available in multiple dosage forms, salts, or combinations, a single representative product is listed. In the case of combination products, the single agent associated with the biomarker is listed unless the agent is only approved as a combination product, in which case all agents are listed.
Download detailed version of the Table of Pharmacogenomic Biomarkers in Drug Labeling with Labeling Text (PDF - 4.3 KB)
Pharmacogenomic Biomarkers in Drug Labeling
| Drug | Therapeutic Area* | Biomarker† | Labeling Sections |
|---|---|---|---|
| Abacavir | Infectious Diseases | HLA-B | Boxed Warning, Dosage and Administration, Contraindications, Warnings and Precautions |
| Abemaciclib (1) | Oncology | ESR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Abemaciclib (2) | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Abemaciclib (3) | Oncology | MKI67 | Clinical Studies |
| Abrocitinib | Dermatology | CYP2C19 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| Adagrasib | Oncology | KRAS | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Ado-Trastuzumab Emtansine | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Aducanumab-avwa | Neurology | APOE | Boxed Warning, Warnings and Precautions, Clinical Studies, Patient Counseling Information |
| Afatinib | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Alectinib | Oncology | ALK | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Alglucosidase Alfa | Inborn Errors of Metabolism | GAA | Warnings and Precautions |
| Allopurinol | Oncology | HLA-B | Warnings |
| Alpelisib (1) | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Alpelisib (2) | Oncology | ESR (Hormone Receptor) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Alpelisib (3) | Oncology | PIK3CA | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Amifampridine Phosphate | Neurology | NAT2 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| Amikacin | Infectious Diseases | MT-RNR1 | Warnings and Precautions |
| Amitriptyline | Psychiatry | CYP2D6 | Precautions |
| Amivantamab-vmjw | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Amoxapine | Psychiatry | CYP2D6 | Precautions |
| Amphetamine | Psychiatry | CYP2D6 | Clinical Pharmacology |
| Anakinra | Rheumatology | NLRP3 | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Anastrozole | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Drug Interactions, Clinical Studies |
| Anifrolumab-fnia | Rheumatology | Gene Signature (IFN) | Clinical Pharmacology, Clinical Studies |
| Arformoterol (1) | Pulmonary | UGT1A1 | Clinical Pharmacology |
| Arformoterol (2) | Pulmonary | CYP2D6 | Clinical Pharmacology |
| Aripiprazole | Psychiatry | CYP2D6 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| Aripiprazole Lauroxil | Psychiatry | CYP2D6 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| Arsenic Trioxide | Oncology | PML-RARA | Indications and Usage, Clinical Studies |
| Articaine and Epinephrine (1) | Anesthesiology | G6PD | Warnings and Precautions |
| Articaine and Epinephrine (2) | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings and Precautions |
| Asciminib | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Ascorbic Acid | Endocrinology | G6PD | Dosage and Administration, Warnings and Precautions, Adverse Reactions, Patient Counseling Information |
| Atezolizumab (1) | Oncology | CD274 (PD-L1) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Atezolizumab (2) | Oncology | Gene Signature (T-effector) | Clinical Studies |
| Atezolizumab (3) | Oncology | EGFR | Indications and Usage, Adverse Reactions, Clinical Studies |
| Atezolizumab (4) | Oncology | ALK | Indications and Usage, Adverse Reactions, Clinical Studies |
| Atezolizumab (5) | Oncology | BRAF | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Atomoxetine | Psychiatry | CYP2D6 | Dosage and Administration, Warnings and Precautions, Adverse Reactions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology |
| Ascorbic Acid, PEG-3350, Potassium Chloride, Sodium Ascorbate, Sodium Chloride, and Sodium Sulfate | Gastroenterology | G6PD | Warnings and Precautions, Adverse Reactions |
| Avapritinib (1) | Oncology | PDGFRA | Indications and Usage, Dosage and Administration, Clinical Studies |
| Avapritinib (2) | Oncology | KIT | Clinical Studies |
| Avatrombopag (1) | Hematology | F2 (Prothrombin) | Warnings and Precautions |
| Avatrombopag (2) | Hematology | F5 (Factor V Leiden) | Warnings and Precautions |
| Avatrombopag (3) | Hematology | PROC | Warnings and Precautions |
| Avatrombopag (4) | Hematology | PROS1 | Warnings and Precautions |
| Avatrombopag (5) | Hematology | SERPINC1 (Antithrombin III) | Warnings and Precautions |
| Avatrombopag (6) | Hematology | CYP2C9 | Clinical Pharmacology |
| Avelumab | Oncology | CD274 (PD-L1) | Clinical Studies |
| Azacitidine (1) | Oncology | CBL | Clinical Studies |
| Azacitidine (2) | Oncology | PTPN11 | Clinical Studies |
| Azacitidine (3) | Oncology | RAS | Clinical Studies |
| Azathioprine (1) | Rheumatology | TPMT | Dosage and Administration, Warnings, Precautions, Drug Interactions, Adverse Reactions, Clinical Pharmacology |
| Azathioprine (2) | Rheumatology | NUDT15 | Dosage and Administration, Warnings, Precautions, Adverse Reactions, Clinical Pharmacology |
| Belinostat | Oncology | UGT1A1 | Dosage and Administration, Clinical Pharmacology |
| Belzutifan (1) | Oncology | CYP2C19 | Drug Interactions, Use in Specific Populations, Clinical Pharmacology |
| Belzutifan (2) | Oncology | UGT2B17 | Drug Interactions, Use in Specific Populations, Clinical Pharmacology |
| Belzutifan (3) | Oncology | VHL | Clinical Studies |
| Bempedoic Acid and Ezetimibe | Endocrinology | Nonspecific (Heterozygous Familial Hypercholesterolemia) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Betaine | Inborn Errors of Metabolism | CBS, MMADHC, MTHFR (Homocystinuria Deficiency) | Indications and Usage, Warnings and Precautions, Clinical Pharmacology, Clinical Studies |
| Binimetinib (1) | Oncology | BRAF | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Binimetinib (2) | Oncology | UGT1A1 | Indications and Usage, Use in Specific Populations |
| Blinatumomab (1) | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Blinatumomab (2) | Oncology | CD19 | Indications and Usage, Use in Specific Populations |
| Boceprevir | Infectious Diseases | IFNL3 (IL28B) | Clinical Pharmacology |
| Bosutinib | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Brentuximab Vedotin (1) | Oncology | ALK | Use in Specific Populations, Clinical Studies |
| Brentuximab Vedotin (2) | Oncology | TNFRSF8 (CD30) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Brexpiprazole | Psychiatry | CYP2D6 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| Brigatinib | Oncology | ALK | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Brivaracetam | Neurology | CYP2C19 | Clinical Pharmacology |
| Bupivacaine (1) | Anesthesiology | G6PD | Warnings |
| Bupivacaine (2) | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings |
| Bupropion | Psychiatry | CYP2D6 | Clinical Pharmacology |
| Bupropion and Dextromethorphan | Psychiatry | CYP2D6 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| Busulfan | Oncology | BCR-ABL1 (Philadelphia chromosome) | Clinical Studies |
| Cabotegravir and Rilpivirine (1) | Infectious Diseases | HLA-B | Clinical Studies |
| Cabotegravir and Rilpivirine (2) | Infectious Diseases | UGT1A1 | Clinical Pharmacology |
| Cabozantinib | Oncology | RET | Clinical Studies |
| Capmatinib | Oncology | MET | Indications and Usage, Dosage and Administration, Clinical Studies |
| Capecitabine (1) | Oncology | DPYD | Boxed Warning, Dosage and Administration, Warnings and Precautions, Clinical Pharmacology, Patient Counseling Information |
| Capecitabine (2) | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Capivasertib (1) | Oncology | AKT1 | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Capivasertib (2) | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Clinical Studies |
| Capivasertib (3) | Oncology | ESR (Hormone Receptor) | Indications and Usage, Dosage and Administration, Clinical Studies |
| Capivasertib (4) | Oncology | PIK3CA | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Capivasertib (5) | Oncology | PTEN | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Carbamazepine (1) | Neurology | HLA-B | Boxed Warning, Warnings, Precautions |
| Carbamazepine (2) | Neurology | HLA-A | Warnings |
| Carglumic Acid | Inborn Errors of Metabolism | NAGS | Indications and Usage, Dosage and Administration, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Cariprazine | Psychiatry | CYP2D6 | Clinical Pharmacology |
| Carisoprodol | Rheumatology | CYP2C19 | Use in Specific Populations, Clinical Pharmacology |
| Carvedilol | Cardiology | CYP2D6 | Drug Interactions, Clinical Pharmacology |
| Casimersen | Neurology | DMD | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Ceftriaxone (1) | Infectious Diseases | G6PD | Warnings |
| Ceftriaxone (2) | Infectious Diseases | Nonspecific (Congenital Methemoglobinemia) | Warnings |
| Celecoxib | Rheumatology | CYP2C9 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| Cemiplimab-rwlc (1) | Oncology | ALK | Indications and Usage, Clinical Studies |
| Cemiplimab-rwlc (2) | Oncology | CD274 (PD-L1) | Indications and Usage, Dosage and Administration, Clinical Studies |
| Cemiplimab-rwlc (3) | Oncology | EGFR | Indications and Usage, Clinical Studies |
| Cemiplimab-rwlc (4) | Oncology | ROS1 | Indications and Usage, Clinical Studies |
| Ceritinib | Oncology | ALK | Indications and Usage, Dosage and Administration, Warning and Precautions, Adverse Reactions, Clinical Studies |
| Cerliponase Alfa | Inborn Errors of Metabolism | TPP1 | Indications and Usage, Use in Specific Populations, Clinical Studies |
| Cetuximab (1) | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Cetuximab (2) | Oncology | RAS | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Studies |
| Cetuximab (3) | Oncology | BRAF | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Cevimeline | Dental | CYP2D6 | Precautions |
| Chloroprocaine (1) | Anesthesiology | G6PD | Warnings |
| Chloroprocaine (2) | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings |
| Chloroquine | Infectious Diseases | G6PD | Precautions, Adverse Reactions |
| Chlorpropamide | Endocrinology | G6PD | Precautions |
| Cholic Acid | Inborn Errors of Metabolism | AMACR, AKR1D1, CYP7A1, CYP27A1, DHCR7, HSD3B2 (Bile Acid Synthesis Disorders) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Cisplatin | Oncology | TPMT | Adverse Reactions |
| Citalopram (1) | Psychiatry | CYP2C19 | Dosage and Administration, Warnings, Clinical Pharmacology |
| Citalopram (2) | Psychiatry | CYP2D6 | Clinical Pharmacology |
| Clobazam | Neurology | CYP2C19 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| Clomipramine | Psychiatry | CYP2D6 | Precautions |
| Clopidogrel | Cardiology | CYP2C19 | Boxed Warning, Warnings and Precautions, Clinical Pharmacology |
| Clozapine | Psychiatry | CYP2D6 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| Cobimetinib | Oncology | BRAF | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Codeine | Anesthesiology | CYP2D6 | Boxed Warning, Warnings and Precautions, Use in Specific Populations, Patient Counseling Information |
| Crizanlizumab-tmca | Hematology | HBB | Adverse Reactions, Clinical Studies |
| Crizotinib (1) | Oncology | ALK | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Crizotinib (2) | Oncology | ROS1 | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Dabrafenib (1) | Oncology | BRAF | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Dabrafenib (2) | Oncology | G6PD | Warnings and Precautions, Adverse Reactions, Patient Counseling Information |
| Dabrafenib (3) | Oncology | RAS | Dosage and Administration, Warnings and Precautions |
| Daclatasvir | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| Dacomitinib | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Dapsone (1) | Dermatology | G6PD | Warnings and Precautions, Use in Specific Populations, Patient Counseling Information |
| Dapsone (2) | Dermatology | Nonspecific (Congenital Methemoglobinemia) | Warnings and Precautions, Adverse Reactions, Patient Counseling Information |
| Dapsone (3) | Infectious Diseases | G6PD | Precautions, Adverse Reactions, Overdosage |
| Darifenacin | Urology | CYP2D6 | Clinical Pharmacology |
| Dasabuvir, Ombitasvir, Paritaprevir, and Ritonavir | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| Dasatinib | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Denileukin Diftitox | Oncology | IL2RA (CD25 antigen) | Indications and Usage, Clinical Studies |
| Desipramine | Psychiatry | CYP2D6 | Precautions |
| Desflurane | Anesthesiology | CACNA1S, RYR1 (Genetic Susceptibility to Malignant Hyperthermia) | Contraindications, Warnings and Precautions, Clinical Pharmacology |
| Desmopressin | Hematology | F8 | Indications and Usage, Dosage and Administration, Clinical Pharmacology |
| Desvenlafaxine | Psychiatry | CYP2D6 | Clinical Pharmacology |
| Deutetrabenazine | Neurology | CYP2D6 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| Dexlansoprazole | Gastroenterology | CYP2C19 | Drug Interactions, Clinical Pharmacology |
| Dextromethorphan and Quinidine | Neurology | CYP2D6 | Warnings and Precautions, Clinical Pharmacology |
| Diazepam | Neurology | CYP2C19 | Clinical Pharmacology |
| Dinutuximab | Oncology | MYCN | Clinical Studies |
| Docetaxel | Oncology | ESR, PGR (Hormone Receptor) | Clinical Studies |
| Dolutegravir | Infectious Diseases | UGT1A1 | Clinical Pharmacology |
| Donepezil | Neurology | CYP2D6 | Clinical Pharmacology |
| Dostarlimab-gxly | Oncology | Microsatellite Instability, Mismatch Repair | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Doxepin (1) | Psychiatry | CYP2D6 | Dosage and Administration, Use in Specific Populations |
| Doxepin (2) | Psychiatry | CYP2C19 | Dosage and Administration, Use in Specific Populations |
| Dronabinol | Gastroenterology | CYP2C9 | Use in Specific Populations, Clinical Pharmacology |
| Drospirenone and Ethinyl Estradiol | Gynecology | CYP2C19 | Clinical Pharmacology |
| Duloxetine | Psychiatry | CYP2D6 | Drug Interactions |
| Durvalumab (1) | Oncology | ALK | Indications and Usage, Clinical Studies |
| Durvalumab (2) | Oncology | EGFR | Indications and Usage, Clinical Studies |
| Durvalumab (3) | Oncology | CD274 (PD-L1) | Clinical Studies |
| Durvalumab (4) | Oncology | Mismatch Repair | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Duvelisib | Oncology | Chromosome 17p | Clinical Studies |
| Eculizumab (1) | Neurology | ACHR | Indications and Usage, Clinical Studies |
| Eculizumab (2) | Neurology | AQP4 | Indications and Usage, Clinical Studies |
| Efavirenz | Infectious Diseases | CYP2B6 | Warnings and Precautions, Clinical Pharmacology |
| Efgartigimod Alfa-fcab | Neurology | ACHR | Indications and Usage, Clinical Pharmacology, Clinical Studies |
| Eflornithine | Oncology | MYCN | Adverse Reactions, Clinical Studies |
| Elacestrant (1) | Oncology | ESR (Hormone Receptor) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Elacestrant (2) | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Elagolix | Gynecology | SLCO1B1 | Clinical Pharmacology |
| Elbasvir and Grazoprevir | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| Elexacaftor, Ivacaftor, and Tezacaftor | Pulmonary | CFTR | Indications and Usage, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Eliglustat | Inborn Errors of Metabolism | CYP2D6 | Indications and Usage, Dosage and Administration, Contraindications, Warnings and Precautions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Elranatamab-bcmm (1) | Oncology | Chromosome 17p | Clinical Studies |
| Elranatamab-bcmm (2) | Oncology | Chromosome 4p;14q | Clinical Studies |
| Elranatamab-bcmm (3) | Oncology | Chromosome 14q;16q | Clinical Studies |
| Elosulfase | Inborn Errors of Metabolism | GALNS | Indications and Usage, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Eltrombopag (1) | Hematology | F5 (Factor V Leiden) | Warnings and Precautions |
| Eltrombopag (2) | Hematology | SERPINC1 (Antithrombin III) | Warnings and Precautions |
| Eltrombopag (3) | Hematology | Chromosome 7 | Adverse Reactions |
| Eltrombopag (4) | Hematology | Chromosome 13 | Adverse Reactions |
| Emapalumab-lzsg | Hematology | PRF1, RAB27A, SH2D1A, STXBP2, STX11, UNC13D, XIAP (Hemophagocytic Lymphohistiocytosis) | Clinical Studies |
| Enasidenib | Oncology | IDH2 | Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies |
| Encorafenib (1) | Oncology | BRAF | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies, Patient Counseling Information |
| Encorafenib (2) | Oncology | RAS | Dosage and Administration, Warnings and Precautions, Clinical Studies |
| Entrectinib (1) | Oncology | ROS1 | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Entrectinib (2) | Oncology | NTRK | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Eplontersen | Neurology | TTR | Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Erdafitinib (1) | Oncology | FGFR3 | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies, Patient Counseling Information |
| Erdafitinib (2) | Oncology | CYP2C9 | Use in Specific Populations, Clinical Pharmacology |
| Eribulin (1) | Oncology | ERBB2 (HER2) | Clinical Studies |
| Eribulin (2) | Oncology | ESR, PGR (Hormone Receptor) | Clinical Studies |
| Erlotinib | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Erythromycin and Sulfisoxazole | Infectious Diseases | G6PD | Precautions |
| Escitalopram (1) | Psychiatry | CYP2D6 | Drug Interactions |
| Escitalopram (2) | Psychiatry | CYP2C19 | Adverse Reactions |
| Esomeprazole | Gastroenterology | CYP2C19 | Drug Interactions, Clinical Pharmacology |
| Estradiol and Progesterone (1) | Gynecology | PROC | Contraindications |
| Estradiol and Progesterone (2) | Gynecology | PROS1 | Contraindications |
| Estradiol and Progesterone (3) | Gynecology | SERPINC1 (Antithrombin III) | Contraindications |
| Estradiol Valerate | Gynecology | ESR, PGR (Hormone Receptor) | Warnings |
| Eteplirsen | Neurology | DMD | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Etrasimod | Gastroenterology | CYP2C9 | Drug Interactions, Use in Specific Populations, Clinical Pharmacology |
| Everolimus (1) | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Everolimus (2) | Oncology | ESR (Hormone Receptor) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Evinacumab-dgnb (1) | Endocrinology | LDLR | Clinical Studies |
| Evinacumab-dgnb (2) | Endocrinology | Nonspecific (Homozygous Familial Hypercholesterolemia) | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Evolocumab (1) | Endocrinology | Nonspecific (Heterozygous Familial Hypercholesterolemia) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Evolocumab (2) | Endocrinology | Nonspecific (Homozygous Familial Hypercholesterolemia) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Exemestane | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Dosage and Administration, Clinical Studies |
| Fam-Trastuzumab Deruxtecan-nxki (1) | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Fam-Trastuzumab Deruxtecan-nxki (2) | Oncology | ESR (Hormone Receptor) | Indications and Usage, Clinical Studies |
| Fesoterodine | Urology | CYP2D6 | Drug Interactions, Clinical Pharmacology |
| Fosphenytoin (1) | Neurology | CYP2C9 | Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology |
| Fosphenytoin (2) | Neurology | HLA-B | Warnings and Precautions |
| Flibanserin (1) | Gynecology | CYP2C9 | Clinical Pharmacology |
| Flibanserin (2) | Gynecology | CYP2C19 | Adverse Reactions, Use in Specific Populations, Clinical Pharmacology |
| Flibanserin (3) | Gynecology | CYP2D6 | Clinical Pharmacology |
| Fluorouracil (1) | Dermatology | DPYD | Contraindications, Warnings |
| Fluorouracil (2) | Oncology | DPYD | Warnings and Precautions, Clinical Pharmacology, Patient Counseling Information |
| Fluoxetine | Psychiatry | CYP2D6 | Warnings and Precautions, Drug Interactions, Clinical Pharmacology |
| Flurbiprofen | Rheumatology | CYP2C9 | Clinical Pharmacology |
| Flutamide | Oncology | G6PD | Warnings |
| Fluvoxamine | Psychiatry | CYP2D6 | Drug Interactions |
| Formoterol (1) | Pulmonary | CYP2D6 | Clinical Pharmacology |
| Formoterol (2) | Pulmonary | CYP2C19 | Clinical Pharmacology |
| Fosdenopterin | Neurology | MOCS1 | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Fruquintinib | Oncology | RAS | Indications and Usage, Clinical Studies |
| Fulvestrant (1) | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Fulvestrant (2) | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Futibatinib | Oncology | FGFR2 | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Galantamine | Neurology | CYP2D6 | Clinical Pharmacology |
| Ganaxolone | Neurology | CDKL5 | Indications and Usage, Clinical Studies |
| Gefitinib (1) | Oncology | EGFR | Indications and Usage, Dosage and Administration, Clinical Studies |
| Gefitinib (2) | Oncology | CYP2D6 | Clinical Pharmacology |
| Gemtuzumab Ozogamicin | Onoclogy | CD33 | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Gentamicin | Infectious Diseases | MT-RNR1 | Warnings |
| Gilteritinib | Oncology | FLT3 | Indications and Usage, Dosage and Administration, Clinical Studies |
| Givosiran | Gastroenterology | CPOX, HMBS, PPOX (Acute Hepatic Porphyria) | Clinical Studies |
| Glimepiride | Endocrinology | G6PD | Warnings and Precautions, Adverse Reactions |
| Glipizide | Endocrinology | G6PD | Precautions |
| Glyburide | Endocrinology | G6PD | Precautions |
| Glycerol Phenylbutyrate (1) | Inborn Errors of Metabolism | ASS1, CPS1, OTC (Urea Cycle Disorders) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Glycerol Phenylbutyrate (2) | Inborn Errors of Metabolism | NAGS | Indications and Usage |
| Golodirsen | Neurology | DMD | Indications and Usage, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Goserelin | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Clinical Studies |
| Hydralazine | Cardiology | Nonspecific (NAT) | Clinical Pharmacology |
| Hydroxychloroquine | Infectious Diseases | G6PD | Warnings and Precautions, Adverse Reactions |
| Ibrutinib (1) | Oncology | Chromosome 17p | Indications and Usage, Clinical Studies |
| Ibrutinib (2) | Oncology | Chromosome 11q | Clinical Studies |
| Ibrutinib (3) | Oncology | MYD88 | Clinical Studies |
| Iloperidone | Psychiatry | CYP2D6 | Dosage and Administration, Warnings and Precautions, Drug Interactions, Clinical Pharmacology |
| Imatinib (1) | Oncology | KIT | Indications and Usage, Dosage and Administration, Clinical Studies |
| Imatinib (2) | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Imatinib (3) | Oncology | PDGFRB | Indications and Usage, Dosage and Administration, Clinical Studies |
| Imatinib (4) | Oncology | FIP1L1-PDGFRA | Indications and Usage, Dosage and Administration, Clinical Studies |
| Imipramine | Psychiatry | CYP2D6 | Precautions |
| Inclisiran | Endocrinology | Nonspecific (Heterozygous Familial Hypercholesterolemia) | Indications and Usage, Clinical Studies |
| Indacaterol | Pulmonary | UGT1A1 | Clinical Pharmacology |
| Inebilizumab-cdon | Neurology | AQP4 | Indications and Usage, Clinical Studies |
| Inotersen | Neurology | TTR | Adverse Reactions, Clinical Pharmacology |
| Inotuzumab Ozogamicin | Oncology | BCR-ABL1 (Philadelphia chromosome) | Clinical Studies |
| Ipilimumab (1) | Oncology | HLA-A | Clinical Studies |
| Ipilimumab (2) | Oncology | Microsatellite Instability, Mismatch Repair | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Ipilimumab (3) | Oncology | CD274 (PD-L1) | Indications and Usage, Dosage and Administration, Use in Specific Populations, Clinical Studies |
| Ipilimumab (4) | Oncology | ALK | Indications and Usage, Adverse Reactions, Clinical Studies |
| Ipilimumab (5) | Oncology | EGFR | Indications and Usage, Adverse Reactions, Clinical Studies |
| Irinotecan | Oncology | UGT1A1 | Dosage and Administration, Clinical Pharmacology, Clinical Studies |
| Isatuximab- irfc (1) | Oncology | Chromosome 17p | Clinical Studies |
| Isatuximab- irfc (2) | Oncology | Chromosome 4p;14q | Clinical Studies |
| Isatuximab- irfc (3) | Oncology | Chromosome 14q;16q | Clinical Studies |
| Isoflurane | Anesthesiology | CACNA1S, RYR1 (Genetic Susceptibility to Malignant Hyperthermia) | Contraindications, Warnings, Clinical Pharmacology |
| Isoniazid, Pyrazinamide, and Rifampin | Infectious Diseases | Nonspecific (NAT) | Clinical Pharmacology |
| Isosorbide Dinitrate | Cardiology | CYB5R | Overdosage |
| Isosorbide Mononitrate | Cardiology | CYB5R | Overdosage |
| Ivacaftor | Pulmonary | CFTR | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Ivacaftor and Lumacaftor | Pulmonary | CFTR | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Ivacaftor and Tezacaftor | Pulmonary | CFTR | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Ivosidenib | Oncology | IDH1 | Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies |
| Ixabepilone (1) | Oncology | ERBB2 (HER2) | Clinical Studies |
| Ixabepilone (2) | Oncology | ESR, PGR (Hormone Receptor) | Clinical Studies |
| Lacosamide | Neurology | CYP2C19 | Clinical Pharmacology |
| Lansoprazole | Gastroenterology | CYP2C19 | Drug Interactions, Clinical Pharmacology |
| Lapatinib (1) | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Lapatinib (2) | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Lapatinib (3) | Oncology | HLA-DQA1 | Clinical Pharmacology |
| Lapatinib (4) | Oncology | HLA-DRB1 | Clinical Pharmacology |
| Larotrectinib | Oncology | NTRK | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Lecanemab-irmb | Neurology | APOE | Boxed Warning, Warnings and Precautions, Clinical Studies, Patient Counseling Information |
| Ledipasvir and Sofosbuvir | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| Lenalidomide | Hematology | Chromosome 5q | Boxed Warning, Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Leniolisib (1) | Pulmonary | PIK3CD | Clinical Studies |
| Leniolisib (2) | Pulmonary | PIK3R1 | Clinical Studies |
| Lenvatinib | Oncology | Microsatellite Instability, Mismatch Repair | Indications and Usage, Adverse Reactions, Clinical Studies |
| Lesinurad | Rheumatology | CYP2C9 | Drug Interactions, Clinical Pharmacology |
| Letrozole | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Levothyroxine | Endocrinology | Nonspecific (Congenital Hypothyroidism) | Indications and Usage, Warnings and Precautions, Use in Specific Populations |
| Lidocaine and Prilocaine (1) | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings and Precautions |
| Lidocaine and Prilocaine (2) | Anesthesiology | G6PD | Warnings and Precautions, Clinical Pharmacology |
| Lidocaine and Tetracaine (1) | Anesthesiology | G6PD | Warnings and Precautions |
| Lidocaine and Tetracaine (2) | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings and Precautions |
| Lofexidine | Anesthesiology | CYP2D6 | Use in Specific Populations |
| Lomitapide | Endocrinology | Nonspecific (Homozygous Familial Hypercholesterolemia) | Indications and Usage, Warnings and Precautions, Adverse Reactions, Clinical Studies |
| Lonafarnib (1) | Inborn Errors of Metabolism | LMNA | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Lonafarnib (2) | Inborn Errors of Metabolism | ZMPSTE24 | Indications and Usage, Use in Specific Populations |
| Lorlatinib (1) | Oncology | ALK | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Lorlatinib (2) | Oncology | ROS1 | Adverse Reactions |
| Lumasiran | Urology | AGXT | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Luspatercept–aamt | Hematology | HBB | Clinical Studies |
| Lusutrombopag (1) | Hematology | F2 (Prothrombin) | Warnings and Precautions |
| Lusutrombopag (2) | Hematology | F5 (Factor V Leiden) | Warnings and Precautions |
| Lusutrombopag (3) | Hematology | PROC | Warnings and Precautions |
| Lusutrombopag (4) | Hematology | PROS1 | Warnings and Precautions |
| Lusutrombopag (5) | Hematology | SERPINC1 (Antithrombin III) | Warnings and Precautions |
| Lutetium Lu 177 Dotatate | Oncology | SSTR | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Lutetium Lu 177 Vipivotide Tetraxetan | Oncology | FOLH1 (PSMA) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Mafenide | Infectious Diseases | G6PD | Warnings, Adverse Reactions |
| Maralixibat (1) | Gastroenterology | JAG1 | Clinical Studies |
| Maralixibat (2) | Gastroenterology | ABCB4 | Clinical Pharmacology, Clinical Studies |
| Maralixibat (3) | Gastroenterology | ABCB11 | Indications and Usage, Clinical Pharmacology, Clinical Studies |
| Maralixibat (4) | Gastroenterology | ATP8B1 | Clinical Pharmacology, Clinical Studies |
| Maralixibat (5) | Gastroenterology | MYO5B | Clinical Pharmacology, Clinical Studies |
| Maralixibat (6) | Gastroenterology | TJP2 | Clinical Pharmacology, Clinical Studies |
| Margetuximab-cmkb (1) | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Margetuximab-cmkb (2) | Oncology | FCGR2A (CD32A) | Clinical Pharmacology |
| Margetuximab-cmkb (3) | Oncology | FCGR2B (CD32B) | Clinical Pharmacology |
| Margetuximab-cmkb (4) | Oncology | FCGR3A (CD16A) | Clinical Pharmacology |
| Mavacamten | Cardiology | CYP2C19 | Dosage and Administration, Clinical Pharmacology |
| Mavorixafor | Hematology | CXCR4 | Clinical Studies |
| Mecasermin | Endocrinology | Nonspecific (GH) | Indications and Usage, Clinical Studies |
| Meclizine | Neurology | CYP2D6 | Warnings and Precautions |
| Medroxyprogesterone | Gynecology | ESR (Hormone Receptor) | Warnings |
| Meloxicam | Anesthesiology | CYP2C9 | Use in Specific Populations, Clinical Pharmacology |
| Mepivacaine (1) | Anesthesiology | G6PD | Warnings |
| Mepivacaine (2) | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings |
| Mepolizumab | Oncology | FIP1L1-PDGFRA | Adverse Reactions, Clinical Studies |
| Mercaptopurine (1) | Oncology | TPMT | Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology |
| Mercaptopurine (2) | Oncology | NUDT15 | Dosage and Administration, Warnings and Precautions, Clinical Pharmacology |
| Methylene Blue | Hematology | G6PD | Contraindications, Warnings and Precautions |
| Metoclopramide (1) | Gastroenterology | CYB5R | Use in Specific Populations |
| Metoclopramide (2) | Gastroenterology | G6PD | Use in Specific Populations, Overdosage |
| Metoclopramide (3) | Gastroenterology | CYP2D6 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| Metoprolol | Cardiology | CYP2D6 | Clinical Pharmacology |
| Metreleptin | Endocrinology | LEP | Contraindications |
| Midostaurin (1) | Oncology | FLT3 | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Midostaurin (2) | Oncology | NPM1 | Clinical Studies |
| Midostaurin (3) | Oncology | KIT | Clinical Studies |
| Migalastat | Inborn Errors of Metabolism | GLA | Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies |
| Mirabegron | Urology | CYP2D6 | Clinical Pharmacology |
| Mirvetuximab Soravtansine-gynx | Oncology | FOLR1 | Indications and Usage, Dosage and Administration, Clinical Studies |
| Mitapivat | Hematology | PKLR | Clinical Studies |
| Mivacurium | Anesthesiology | BCHE | Warnings, Precautions, Clinical Pharmacology |
| Mobocertinib | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Modafinil | Psychiatry | CYP2D6 | Clinical Pharmacology |
| Mycophenolic Acid | Transplantation | HPRT1 | Warnings and Precautions |
| Nalidixic Acid | Infectious Diseases | G6PD | Precautions, Adverse Reactions |
| Nateglinide | Endocrinology | CYP2C9 | Drug Interactions |
| Nebivolol | Cardiology | CYP2D6 | Dosage and Administration, Clinical Pharmacology |
| Nedosiran | Nephrology | AGXT | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Nefazodone | Psychiatry | CYP2D6 | Precautions |
| Neomycin | Infectious Diseases | MT-RNR1 | Warnings |
| Neratinib (1) | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Neratinib (2) | Oncology | ESR, PGR (Hormone Receptor) | Clinical Studies |
| Nilotinib (1) | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Nilotinib (2) | Oncology | UGT1A1 | Clinical Pharmacology |
| Niraparib | Oncology | BRCA (Homologous Recombination Deficiency) | Indications and Usage, Dosage and Administration, Clinical Studies |
| Nitrofurantoin | Infectious Diseases | G6PD | Warnings, Adverse Reactions |
| Nirogacestat (1) | Oncology | APC | Clinical Studies |
| Nirogacestat (2) | Oncology | CTNNB1 | Clinical Studies |
| Nivolumab (1) | Oncology | BRAF | Adverse Reactions, Clinical Studies |
| Nivolumab (2) | Oncology | CD274 (PD-L1) | Indications and Usage, Dosage and Administration, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Nivolumab (3) | Oncology | Microsatellite Instability, Mismatch Repair | Indications and Usage, Clinical Studies |
| Nivolumab (4) | Oncology | EGFR | Indications and Usage, Adverse Reactions, Clinical Studies |
| Nivolumab (5) | Oncology | ALK | Indications and Usage, Adverse Reactions, Clinical Studies |
| Nivolumab (6) | Oncology | ERBB2 (HER2) | Adverse Reactions, Clinical Studies |
| Nivolumab and Relatlimab-rmbw (1) | Oncology | BRAF | Clinical Studies |
| Nivolumab and Relatlimab-rmbw (2) | Oncology | CD274 (PD-L1) | Clinical Studies |
| Nivolumab and Relatlimab-rmbw (3) | Oncology | LAG3 | Clinical Studies |
| Nortriptyline | Psychiatry | CYP2D6 | Precautions |
| Nusinersen | Neurology | SMN2 | Clinical Pharmacology, Clinical Studies |
| Obinutuzumab | Oncology | MS4A1 (CD20 antigen) | Clinical Studies |
| Odevixibat (1) | Gastroenterology | ABCB11 | Indications and Usage, Clinical Pharmacology, Clinical Studies |
| Odevixibat (2) | Gastroenterology | ATP8B1 | Indications and Usage, Clinical Pharmacology, Clinical Studies |
| Odevixibat (3) | Gastroenterology | JAG1 | Clinical Studies |
| Odevixibat (4) | Gastroenterology | NOTCH2 | Clinical Studies |
| Olaparib (1) | Oncology | BRCA | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Studies |
| Olaparib (2) | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Olaparib (3) | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Clinical Studies |
| Olaparib (4) | Oncology | BRCA, Genomic Instability (Homologous Recombination Deficiency) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Olaparib (5) | Oncology | Homologous Recombination Repair | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Olaparib (6) | Oncology | PPP2R2A | Clinical Studies |
| Olaratumab | Oncology | PDGFRA | Clinical Studies |
| Oliceridine | Anesthesiology | CYP2D6 | Warnings and Precautions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology |
| Olutasidenib | Oncology | IDH1 | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Omacetaxine | Oncology | BCR-ABL1 (Philadelphia chromosome) | Clinical Studies |
| Ombitasvir, Paritaprevir, and Ritonavir | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| Omeprazole | Gastroenterology | CYP2C19 | Drug Interactions, Clinical Pharmacology |
| Oxymetazoline and Tetracaine (1) | Anesthesiology | G6PD | Warnings and Precautions |
| Oxymetazoline and Tetracaine (2) | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings and Precautions |
| Ondansetron | Gastroenterology | CYP2D6 | Clinical Pharmacology |
| Osimertinib | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Ospemifene (1) | Gynecology | CYP2C9 | Clinical Pharmacology |
| Ospemifene (2) | Gynecology | CYP2B6 | Clinical Pharmacology |
| Oxcarbazepine | Neurology | HLA-B | Warnings and Precautions |
| Palbociclib (1) | Oncology | ESR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Palbociclib (2) | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Paliperidone | Psychiatry | CYP2D6 | Clinical Pharmacology |
| Palonosetron | Gastroenterology | CYP2D6 | Clinical Pharmacology |
| Panitumumab (1) | Oncology | EGFR | Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Panitumumab (2) | Oncology | RAS | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Studies |
| Pantoprazole | Gastroenterology | CYP2C19 | Clinical Pharmacology |
| Parathyroid Hormone | Inborn Errors of Metabolism | CASR | Indications and Usage, Clinical Studies |
| Paroxetine | Psychiatry | CYP2D6 | Drug Interactions, Clinical Pharmacology |
| Patisiran | Neurology | TTR | Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Pazopanib (1) | Oncology | UGT1A1 | Clinical Pharmacology |
| Pazopanib (2) | Oncology | HLA-B | Clinical Pharmacology |
| Peginterferon Alfa-2b | Infectious Diseases | IFNL3 (IL28B) | Clinical Pharmacology |
| Pegloticase | Rheumatology | G6PD | Boxed Warning, Contraindications, Warnings and Precautions, Adverse Reactions, Patient Counseling Information |
| Pembrolizumab (1) | Oncology | BRAF | Adverse Reactions, Clinical Studies |
| Pembrolizumab (2) | Oncology | CD274 (PD-L1) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Pembrolizumab (3) | Oncology | Microsatellite Instability, Mismatch Repair | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Pembrolizumab (4) | Oncology | EGFR | Indications and Usage, Adverse Reactions, Clinical Studies |
| Pembrolizumab (5) | Oncology | ALK | Indications and Usage, Adverse Reactions, Clinical Studies |
| Pembrolizumab (6) | Oncology | Tumor Mutational Burden | Indications and Usage, Dosage and Administration, Use in Specific Populations, Clinical Studies |
| Pembrolizumab (7) | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Pemetrexed (1) | Oncology | ALK | Indications and Usage, Adverse Reactions, Clinical Studies |
| Pemetrexed (2) | Oncology | EGFR | Indications and Usage, Adverse Reactions, Clinical Studies |
| Pemetrexed (3) | Oncology | CD274 (PD-L1) | Clinical Studies |
| Pemigatinib (1) | Oncology | FGFR1 | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Pemigatinib (2) | Oncology | FGFR2 | Indications and Usage, Dosage and Administration, Clinical Studies |
| Perphenazine | Psychiatry | CYP2D6 | Precautions, Clinical Pharmacology |
| Pertuzumab (1) | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Pertuzumab (2) | Oncology | ESR, PGR (Hormone Receptor) | Clinical Studies |
| Phenytoin (1) | Neurology | CYP2C9 | Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology |
| Phenytoin (2) | Neurology | CYP2C19 | Clinical Pharmacology |
| Phenytoin (3) | Neurology | HLA-B | Warnings and Precautions |
| Pimozide | Psychiatry | CYP2D6 | Dosage and Administration, Precautions |
| Piroxicam | Rheumatology | CYP2C9 | Clinical Pharmacology |
| Pirtobrutinib (1) | Oncology | BTK | Clinical Studies |
| Pirtobrutinib (2) | Oncology | Chromosome 11q | Clinical Studies |
| Pirtobrutinib (3) | Oncology | Chromosome 17p | Clinical Studies |
| Pirtobrutinib (4) | Oncology | IGHV | Clinical Studies |
| Pirtobrutinib (5) | Oncology | TP53 | Clinical Studies |
| Pitavastatin | Endocrinology | Nonspecific (Heterozygous Familial Hypercholesterolemia) | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Pitolisant | Psychiatry | CYP2D6 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| Plazomicin | Infectious Diseases | MT-RNR1 | Warnings and Precautions |
| Polatuzumab Vedotin-piiq (1) | Oncology | BCL2 | Clinical Studies |
| Polatuzumab Vedotin-piiq (2) | Oncology | BCL6 | Clinical Studies |
| Polatuzumab Vedotin-piiq (3) | Oncology | MYC | Clinical Studies |
| Ponatinib | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Pralsetinib | Oncology | CCDC6-RET, KIF5B-RET, RET | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Prasugrel (1) | Cardiology | CYP2C19 | Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Prasugrel (2) | Cardiology | CYP2C9 | Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Prasugrel (3) | Cardiology | CYP3A5 | Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Prasugrel (4) | Cardiology | CYP2B6 | Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Primaquine (1) | Infectious Diseases | G6PD | Contraindications, Warnings, Precautions, Adverse Reactions, Overdosage |
| Primaquine (2) | Infectious Diseases | CYB5R | Precautions, Adverse Reactions |
| Probenecid | Rheumatology | G6PD | Adverse Reactions |
| Procainamide | Cardiology | Nonspecific (NAT) | Adverse Reactions, Clinical Pharmacology |
| Propafenone | Cardiology | CYP2D6 | Dosage and Administration, Warnings and Precautions, Drug Interactions, Clinical Pharmacology |
| Propranolol | Cardiology | CYP2D6 | Clinical Pharmacology |
| Protriptyline | Psychiatry | CYP2D6 | Precautions |
| Quinidine | Cardiology | CYP2D6 | Precautions |
| Quinine Sulfate (1) | Infectious Diseases | G6PD | Warnings and Precautions |
| Quinine Sulfate (2) | Infectious Diseases | CYP2D6 | Clinical Pharmacology |
| Quizartinib | Oncology | FLT3 | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Studies |
| Rabeprazole | Gastroenterology | CYP2C19 | Drug Interactions, Clinical Pharmacology |
| Raloxifene | Oncology | ESR (Hormone Receptor) | Clinical Studies |
| Raltegravir | Infectious Diseases | UGT1A1 | Clinical Pharmacology |
| Ramucirumab (1) | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Ramucirumab (2) | Oncology | RAS | Clinical Studies |
| Rasburicase (1) | Oncology | G6PD | Boxed Warning, Contraindications, Warnings and Precautions |
| Rasburicase (2) | Oncology | CYB5R | Boxed Warning, Contraindications, Warnings and Precautions |
| Ravulizumab-cwvz (1) | Neurology | ACHR | Indications and Usage, Clinical Studies |
| Ravulizumab-cwvz (2) | Neurology | AQP4 | Indications and Usage, Clinical Studies |
| Regorafenib | Oncology | RAS | Indications and Usage, Clinical Studies |
| Repotrectinib (1) | Oncology | ROS1 | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Repotrectinib (2) | Oncology | NTRK | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Resmetirom | Gastroenterology | ABCG2 | Clinical Pharmacology |
| Ribociclib (1) | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Ribociclib (2) | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Rimegepant | Neurology | CYP2C9 | Clinical Pharmacology |
| Risdiplam | Neurology | SMN1, SMN2 | Clinical Studies |
| Risperidone | Psychiatry | CYP2D6 | Clinical Pharmacology |
| Rituximab | Oncology | MS4A1 (CD20 antigen) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Rivaroxaban | Cardiology | F5 (Factor V Leiden) | Clinical Studies |
| Ropeginterferon Alfa-2b-njft | Hematology | JAK2 | Clinical Pharmacology, Clinical Studies |
| Ropivacaine (1) | Anesthesiology | G6PD | Warnings |
| Ropivacaine (2) | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings |
| Rosuvastatin | Endocrinology | SLCO1B1 | Clinical Pharmacology |
| Rozanolixizumab-noli (1) | Neurology | ACHR | Indications and Usage, Clinical Pharmacology, Clinical Studies |
| Rozanolixizumab-noli (2) | Neurology | MUSK | Indications and Usage, Clinical Pharmacology, Clinical Studies |
| Rucaparib (1) | Oncology | BRCA | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Rucaparib (2) | Oncology | CYP2D6 | Clinical Pharmacology |
| Rucaparib (3) | Oncology | CYP1A2 | Clinical Pharmacology |
| Rucaparib (4) | Oncology | BRCA, Loss of Heterozygosity (Homologous Recombination Deficiency) | Warnings and Precautions, Adverse Reactions, Clinical Studies |
| Sacituzumab Govitecan-hziy (1) | Oncology | UGT1A1 | Warnings and Precautions, Clinical Pharmacology |
| Sacituzumab Govitecan-hziy (2) | Oncology | BRCA | Clinical Studies |
| Sacituzumab Govitecan-hziy (3) | Oncology | ESR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Sacituzumab Govitecan-hziy (4) | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Sacrosidase | Inborn Errors of Metabolism | Nonspecific (Congenital Sucrase-Isomaltase Deficiency) | Indications and Usage, Adverse Reactions, Clinical Pharmacology |
| Satralizumab-mwge | Neurology | AQP4 | Indications and Usage, Adverse Reactions, Clinical Studies |
| Selpercatinib | Oncology | RET | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Setmelanotide (1) | Endocrinology | LEPR | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Setmelanotide (2) | Endocrinology | PCSK1 | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Setmelanotide (3) | Endocrinology | POMC | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Sevoflurane | Anesthesiology | CACNA1S, RYR1 (Genetic Susceptibility to Malignant Hyperthermia) | Contraindications, Warnings, Clinical Pharmacology |
| Simeprevir | Infectious Diseases | IFNL3 (IL28B) | Clinical Pharmacology, Clinical Studies |
| Siponimod | Neurology | CYP2C9 | Dosage and Administration, Contraindications, Drug Interactions, Use in Specific Populations, Clinical Pharmacology |
| Sodium Nitrite (1) | Toxicology | G6PD | Warnings and Precautions |
| Sodium Nitrite (2) | Toxicology | Nonspecific (Congenital Methemoglobinemia) | Boxed Warning, Warnings and Precautions |
| Sodium Oxybate | Neurology | ALDH5A1 (Succinic Semialdehyde Dehydrogenase Deficiency) | Contraindications |
| Sodium Phenylbutyrate | Inborn Errors of Metabolism | ASS1, CPS1, OTC (Urea Cycle Disorders) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology |
| Sofosbuvir | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| Sofosbuvir and Velpatasvir | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| Sofosbuvir, Velpatasvir, and Voxilaprevir | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| Sotorasib | Oncology | KRAS | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Streptomycin | Infectious Diseases | MT-RNR1 | Warnings |
| Succimer | Hematology | G6PD | Clinical Pharmacology |
| Succinylcholine (1) | Anesthesiology | BCHE | Warnings, Precautions |
| Succinylcholine (2) | Anesthesiology | CACNA1S, RYR1 | Boxed Warning, Contraindications, Warnings, Precautions, Adverse Reactions, Clinical Pharmacology |
| Sulfadiazine | Infectious Diseases | G6PD | Warnings |
| Sulfamethoxazole and Trimethoprim (1) | Infectious Diseases | G6PD | Precautions |
| Sulfamethoxazole and Trimethoprim (2) | Infectious Diseases | Nonspecific (NAT) | Precautions |
| Sulfasalazine (1) | Gastroenterology | G6PD | Precautions |
| Sulfasalazine (2) | Gastroenterology | Nonspecific (NAT) | Clinical Pharmacology |
| Synthetic Conjugated Estrogens, A (1) | Gynecology | PROC | Contraindications |
| Synthetic Conjugated Estrogens, A (2) | Gynecology | PROS1 | Contraindications |
| Synthetic Conjugated Estrogens, A (3) | Gynecology | SERPINC1 (Antithrombin III) | Contraindications |
| Tafamidis | Cardiology | TTR | Clinical Pharmacology, Clinical Studies |
| Tafenoquine | Infectious Diseases | G6PD | Dosage and Administration, Contraindications, Warnings and Precautions, Use in Specific Populations, Patient Counseling Information |
| Talazoparib (1) | Oncology | BRCA | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Talazoparib (2) | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Talazoparib (3) | Oncology | Homologous Recombination Repair | Indications and Usage, Dosage and Administrations, Adverse Reactions, Drug Interactions, Clinical Studies |
| Tamoxifen (1) | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Tamoxifen (2) | Oncology | F5 (Factor V Leiden) | Warnings and Precautions |
| Tamoxifen (3) | Oncology | F2 (Prothrombin) | Warnings and Precautions |
| Tamoxifen (4) | Oncology | CYP2D6 | Clinical Pharmacology |
| Tamsulosin | Urology | CYP2D6 | Warnings and Precautions, Adverse Interactions, Clinical Pharmacology |
| Tebentafusp-tebn | Oncology | HLA-A | Indications and Usage, Dosage and Administration, Clinical Studies |
| Teclistamab-cqyv (1) | Oncology | Chromosome 17p | Clinical Studies |
| Teclistamab-cqyv (2) | Oncology | Chromosome 4p;14q | Clinical Studies |
| Teclistamab-cqyv (3) | Oncology | Chromosome 14q;16q | Clinical Studies |
| Telaprevir | Infectious Diseases | IFNL3 (IL28B) | Clinical Pharmacology, Clinical Studies |
| Tepotinib (1) | Oncology | ALK | Clinical Studies |
| Tepotinib (2) | Oncology | EGFR | Clinical Studies |
| Tepotinib (3) | Oncology | MET | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Tetrabenazine | Neurology | CYP2D6 | Dosage and Administration, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology |
| Thioguanine (1) | Oncology | TPMT | Dosage and Administration, Warnings, Precautions, Clinical Pharmacology |
| Thioguanine (2) | Oncology | NUDT15 | Dosage and Administration, Warnings, Precautions, Clinical Pharmacology |
| Thioridazine | Psychiatry | CYP2D6 | Contraindications, Warnings, Precautions |
| Ticagrelor | Cardiology | CYP2C19 | Clinical Pharmacology |
| Tipiracil and Trifluridine (1) | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Tipiracil and Trifluridine (2) | Oncology | RAS | Indications and Usage, Clinical Studies |
| Tislelizumab-jsgr (1) | Oncology | CD274 (PD-L1) | Indications and Usage, Dosage and Administration, Clinical Studies |
| Tobramycin | Infectious Diseases | MT-RNR1 | Warnings and Precautions |
| Tofersen | Neurology | SOD1 | Indications and Usage, Use in Specific Populations, Clinical Studies |
| Tolazamide | Endocrinology | G6PD | Precautions |
| Tolbutamide | Endocrinology | G6PD | Precautions |
| Tolterodine | Urology | CYP2D6 | Warnings and Precautions, Drug Interactions, Clinical Pharmacology |
| Toremifene | Oncology | ESR (Hormone Receptor) | Indications and Usage, Clinical Studies |
| Tovorafenib | Oncology | BRAF | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Tramadol | Anesthesiology | CYP2D6 | Boxed Warning, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology, Patient Counseling Information |
| Trametinib (1) | Oncology | BRAF | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Trametinib (2) | Oncology | G6PD | Adverse Reactions |
| Trametinib (3) | Oncology | RAS | Warnings and Precautions |
| Trastuzumab (1) | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies |
| Trastuzumab (2) | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Clinical Studies |
| Tretinoin | Oncology | PML-RARA | Indications and Usage, Dosage and Administration, Warnings and Precautions, Patient Counseling Information |
| Triheptanoin | Inborn Errors of Metabolism | ACADVL, CPT2, HADHA, HADHB (Long-Chain Fatty Acid Oxidation Disorders) | Indications and Usage, Clinical Studies |
| Tremelimumab-actl (1) | Oncology | ALK | Indications and Usage, Clinical Studies |
| Tremelimumab-actl (2) | Oncology | EGFR | Indications and Usage, Clinical Studies |
| Tremelimumab-actl (3) | Oncology | CD274 (PD-L1) | Clinical Studies |
| Trimipramine | Psychiatry | CYP2D6 | Precautions |
| Trofinetide | Neurology | MECP2 | Clinical Studies |
| Tucatinib (1) | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Tucatinib (2) | Oncology | Microsatellite Instability, Mismatch Repair | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Tucatinib (3) | Oncology | RAS | Clinical Studies |
| Umeclidinium | Pulmonary | CYP2D6 | Clinical Pharmacology |
| Upadacitinib | Rheumatology | CYP2D6 | Clinical Pharmacology |
| Ustekinumab | Dermatology and Gastroenterology | IL12A, IL12B, IL23A | Warnings and Precautions |
| Valbenazine | Neurology | CYP2D6 | Dosage and Administration, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology |
| Valproic Acid (1) | Neurology | POLG | Boxed Warning, Contraindications, Warnings and Precautions |
| Valproic Acid (2) | Neurology | Nonspecific (Urea Cycle Disorders) | Contraindications, Warnings and Precautions |
| Vemurafenib (1) | Oncology | BRAF | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies, Patient Counseling Information |
| Vemurafenib (2) | Oncology | RAS | Warnings and Precautions, Adverse Reactions |
| Venetoclax (1) | Oncology | Chromosome 17p | Clinical Studies |
| Venetoclax (2) | Oncology | Chromosome 11q | Clinical Studies |
| Venetoclax (3) | Oncology | TP53 | Clinical Studies |
| Venetoclax (4) | Oncology | IDH1 | Clinical Studies |
| Venetoclax (5) | Oncology | IDH2 | Clinical Studies |
| Venetoclax (6) | Oncology | IGHV | Clinical Studies |
| Venetoclax (7) | Oncology | NPM1 | Clinical Studies |
| Venetoclax (8) | Oncology | FLT3 | Clinical Studies |
| Venlafaxine | Psychiatry | CYP2D6 | Drug Interactions, Use in Specific Populations, Clinical Pharmacology |
| Viloxazine (1) | Psychiatry | CYP2D6 | Clinical Pharmacology |
| Viloxazine (2) | Psychiatry | SLCO1B1 | Clinical Pharmacology |
| Viltolarsen | Neurology | DMD | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Vincristine | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Voriconazole | Infectious Diseases | CYP2C19 | Clinical Pharmacology |
| Vortioxetine | Psychiatry | CYP2D6 | Dosage and Administration, Clinical Pharmacology |
| Voxelotor | Hematology | HBB | Clinical Pharmacology, Clinical Studies |
| Vutrisiran | Neurology | TTR | Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Warfarin (1) | Hematology | CYP2C9 | Dosage and Administration, Drug Interactions, Clinical Pharmacology |
| Warfarin (2) | Hematology | VKORC1 | Dosage and Administration, Clinical Pharmacology |
| Warfarin (3) | Hematology | PROS1 | Warnings and Precautions |
| Warfarin (4) | Hematology | PROC | Warnings and Precautions |
| Zanubrutinib (1) | Oncology | MYD88 | Adverse Reactions, Clinical Studies |
| Zanubrutinib (2) | Oncology | Chromosome 17p | Adverse Reactions, Clinical Studies |
| Zanubrutinib (3) | Oncology | TP53 | Clinical Studies |
| Zilucoplan | Neurology | ACHR | Indications and Usage, Clinical Studies |
| Acalabrutinib (1) | Oncology | Chromosome 17p | Clinical Studies |
| Acalabrutinib (2) | Oncology | Chromosome 11q | Clinical Studies |
| Acalabrutinib (3) | Oncology | IGVH | Clinical Studies |
| Acalabrutinib (4) | Oncology | TP53 | Clinical Studies |
| Acoramidis | Cardiology | TTR | Indications and Usage, Clinical Pharmacology, Clinical Studies |
| Aficamten | Cardiology | CYP2C9 | Clinical Pharmacology |
| Avutometinib and Defactinib | Oncology | KRAS | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Belantamab Mafodotin-blmf (1) | Oncology | Chromosome 17p | Clinical Studies |
| Belantamab Mafodotin-blmf (2) | Oncology | Chromosome 11p;14q | Clinical Studies |
| Belantamab Mafodotin-blmf (3) | Oncology | Chromosome 14q;16q | Clinical Studies |
| Brentuximab Vedotin (3) | Oncology | MYC | Clinical Studies |
| Brentuximab Vedotin (4) | Oncology | BCL2 | Clinical Studies |
| Brentuximab Vedotin (5) | Oncology | BCL6 | Clinical Studies |
| Datopotamab Deruxtecan-dlnk (1) | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Datopotamab Deruxtecan-dlnk (2) | Oncology | ESR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Datopotamab Deruxtecan-dlnk (3) | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Dehydrated Alcohol (Ethanol) | Toxicology | ALDH2 | Warnings and Precautions, Clinical Pharmacology |
| Deuruxolitinib | Dermatology | CYP2C9 | Dosage and Administration, Contraindications, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology, Patient Counseling Information |
| Deutivacaftor, Tezacaftor, and Vanzacaftor | Pulmonary | CFTR | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Donanemab-azbt | Neurology | APOE | Boxed Warning, Warnings and Precautions, Clinical Studies, Patient Counseling Information |
| Dordaviprone | Oncology | H3 | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Ensartinib | Oncology | ALK | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Imlunestrant (1) | Oncology | ESR (Hormone Receptor) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Imlunestrant (2) | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Imlunestrant (3) | Oncology | UGT1A1 | Clinical Pharmacology |
| Inavolisib (1) | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Inavolisib (2) | Oncology | ESR (Hormone Receptor) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Inavolisib (3) | Oncology | PIK3CA | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Lamotrigine | Neurology | HLA-B | Boxed Warning, Warnings and Precautions |
| Lazertinib (1) | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Lazertinib (2) | Oncology | GSTM1 | Clinical Pharmacology |
| Linvoseltamab-gcpt (1) | Oncology | Chromosome 17p | Clinical Studies |
| Linvoseltamab-gcpt (2) | Oncology | Chromosome 4p;14q | Clinical Studies |
| Linvoseltamab-gcpt (3) | Oncology | Chromosome 14q;16q | Clinical Studies |
| Nipocalimab-aahu (1) | Neurology | ACHR | Indications and Usage, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Nipocalimab-aahu (2) | Neurology | MUSK | Indications and Usage, Clinical Pharmacology, Clinical Studies |
| Odevixibat (5) | Gastroenterology | ABCB4 | Clinical Pharmacology |
| Odevixibat (6) | Gastroenterology | TJP2 | Clinical Pharmacology |
| Odevixibat (7) | Gastroenterology | MYO5B | Clinical Pharmacology |
| Palbociclib (3) | Oncology | PIK3CA | Indications and Usage, Adverse Reactions, Clinical Studies |
| Penpulimab-kcqx | Oncology | CD274 (PD-L1) | Clinical Studies |
| Primaquine (3) | Infectious Diseases | CYP2D6 | Precautions, Clinical Pharmacology |
| Ramucirumab (3) | Oncology | ALK | Indications and Usage, Clinical Studies |
| Retifanlimab-dlwr | Oncology | CD274 (PD-L1) | Clinical Studies |
| Revumenib (1) | Oncology | NPM1 | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Revumenib (2) | Oncology | KMT2A | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Seladelpar | Gastroenterology | CYP2C9 | Drug Interactions, Use in Specific Populations, Clinical Pharmacology |
| Selumetinib | Oncology | NF1 | Indications and Usage, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Sepiapterin | Inborn Errors of Metabolism | ABCG2 | Clinical Pharmacology |
| Sevabertinib (1) | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Sevabertinib (2) | Oncology | EGFR | Clinical Pharmacology |
| Spesolimab-sbzo | Dermatology | IL36RN | Clinical Studies |
| Sunvozertinib | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Taletrectinib | Oncology | ROS1 | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Telisotuzumab Vedotin-tllv (1) | Oncology | EGFR | Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Telisotuzumab Vedotin-tllv (2) | Oncology | MET | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Tislelizumab-jsgr (2) | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Clinical Studies |
| Trospium and Xanomeline | Psychiatry | CYP2D6 | Clinical Pharmacology |
| Vonoprazan | Gastroenterology | CYP2C19 | Clinical Pharmacology |
| Vorasidenib (1) | Oncology | IDH1 | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Vorasidenib (2) | Oncology | IDH2 | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Zanidatamab-hrii | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Studies |
| Zenocutuzumab-zbco | Oncology | NRG1 | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Ziftomenib (1) | Oncology | NPM1 | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Ziftomenib (2) | Oncology | KMT2A | Warnings and Precautions |
| Zolbetuximab-clzb (1) | Oncology | CLDN | Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies |
| Zolbetuximab-clzb (2) | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies |
| Zongertinib | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
* Therapeutic areas do not necessarily reflect the CDER review division.
† Representative biomarkers are listed based on standard nomenclature as per the Human Genome Organization (HUGO) symbol and/or simplified descriptors using other common conventions. Listed biomarkers do not necessarily reflect the terminology used in labeling. The term “Nonspecific” is provided when labeling does not explicitly identify the specific biomarker(s) or when the biomarker is represented by a molecular phenotype or gene signature, and in some cases the biomarker was inferred based on the labeling language. For detailed information on the biomarkers used in labeling, refer to the Labeling Text PDF.
† Representative biomarkers are listed based on standard nomenclature as per the Human Genome Organization (HUGO) symbol and/or simplified descriptors using other common conventions. Listed biomarkers do not necessarily reflect the terminology used in labeling. The term “Nonspecific” is provided when labeling does not explicitly identify the specific biomarker(s) or when the biomarker is represented by a molecular phenotype or gene signature, and in some cases the biomarker was inferred based on the labeling language. For detailed information on the biomarkers used in labeling, refer to the Labeling Text PDF.